Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
MPM Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
MPM Capital

MPM Capital

Operating

MPM Capital L.P. is a US-based healthcare investment firm, specializing in venture capital for therapeutic areas.

Location
Boston, MA, US
Founded
1996
Firm
Compare
Portfolio
Employees
Website

Investments

Deka Biosciences
Deka Biosciences

Total Raised

$91.4M

Rounds

4

Series B$20MSeptember 2023
ReCode Therapeutics
ReCode Therapeutics

Total Raised

$521.8M

Rounds

6

Series B$50MSeptember 2023
Series B$259.8MOctober 2021
Series A$80MMarch 2020
Arialys Therapeutics
Arialys Therapeutics

Total Raised

$58M

Rounds

1

Seed$58MSeptember 2023
Crossbow Therapeutics
Crossbow Therapeutics
Series B

Total Raised

$157M

Rounds

2

Series A$80MJuly 2023
ElevateBio
ElevateBio

Total Raised

$1.2B

Rounds

5

Series D$401MMay 2023
Series C$525MMarch 2021
Series B$170MMarch 2020
ReNAgade Therapeutics
ReNAgade Therapeutics

Total Raised

$300M

Rounds

1

Series A$300MMay 2023
NextPoint Therapeutics
NextPoint Therapeutics

Total Raised

$80M

Rounds

1

Series B$80MJanuary 2023
Photys Therapeutics
Photys Therapeutics

Total Raised

$75M

Rounds

1

Series A$75MSeptember 2022
Aktis Oncology
Aktis Oncology

Total Raised

$156M

Rounds

2

Series A$84MAugust 2022
Series A$72MMarch 2021
Orna Therapeutics
Orna Therapeutics

Total Raised

$321M

Rounds

3

Series B$221MAugust 2022
Series A$80MFebruary 2021
Coda Biotherapeutics
Coda Biotherapeutics

Total Raised

$62.7M

Rounds

5

Series Unknown$28MDecember 2021
Protego Biopharma
Protego Biopharma

Total Raised

$51M

Rounds

1

Series A$51MOctober 2021
Frontier Medicines
Frontier Medicines

Total Raised

$244M

Rounds

3

Series B$88.5MJuly 2021
Entrada Therapeutics
Entrada Therapeutics
Public

Total Raised

$201.6M

Rounds

5

Series B$116MMarch 2021
Werewolf Therapeutics
Werewolf Therapeutics
Public

Total Raised

$128.2M

Rounds

3

Series B$72MJanuary 2021
Cullinan Oncology
Cullinan Oncology
Public

Total Raised

$389.7M

Rounds

5

Series C$131.2MDecember 2020
Series B$98.5MJune 2020
Umoja Biopharma
Umoja Biopharma

Total Raised

$263M

Rounds

3

Series A$53MNovember 2020
iTeos Therapeutics
iTeos Therapeutics
Public

Total Raised

$242.7M

Rounds

9

Series B$125MApril 2020